Last Updated on December 22, 2024 by The Health Master
USFDA approval
Glenmark Pharmaceuticals, a leading global pharmaceutical company, has secured a significant win with the U.S. Food and Drug Administration approval (USFDA approval) for its Topiramate Capsules USP in 15 mg and 25 mg strengths.
This generic medication presents a compelling alternative for patients seeking treatment for specific types of seizures, and Glenmark is poised to tap into a sizeable market opportunity.
Bioequivalent and Therapeutically Equivalent to Brand Leader
The USFDA’s rigorous evaluation process confirmed that Glenmark’s Topiramate capsules are bioequivalent and therapeutically equivalent to Topamax capsules, 15 mg and 25 mg, offered by Janssen Pharmaceuticals.
This signifies that Glenmark’s product delivers the same level of efficacy and safety as the brand leader, ensuring patients have a reliable and cost-effective treatment option.
Targeting a $21.9 Million Market Segment
According to IQVIA, a leading healthcare research firm, the combined market for Topamax capsules in the 15 mg and 25 mg strengths reached approximately $21.9 million in annual sales for the 12-month period ending May 2024.
This data underscores the significant demand for this type of medication and positions Glenmark to capture a substantial share of this market.
Expanding Glenmark’s US Portfolio
This USFDA approval marks a significant milestone for Glenmark in the US market.
With the addition of Topiramate capsules, their current portfolio boasts 198 products authorized for distribution, further solidifying their presence in the region.
Additionally, Glenmark has 50 ANDAs (Abbreviated New Drug Applications) pending approval with the USFDA, demonstrating their commitment to expanding their product offerings and catering to diverse patient needs.
Strategic Growth
Beyond internal filings, Glenmark actively pursues external development partnerships to accelerate the growth of its pipeline and portfolio.
This strategic approach allows them to leverage expertise and resources beyond their own organization, bringing innovative and life-changing medications to patients faster.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA approval granted for the drug used for Colon Cleansing
USFDA approval granted for the drug for the treatment of Migraine
USFDA approval granted for this chronic heart failure treatment drug
USFDA approval granted for generic Bromfenac Ophthalmic Solution
USFDA declines to approve this Nasal Spray
USFDA inspection concluded at Divi’s Labs with one observation
Yoga may be beneficial in Rheumatoid Arthritis: AIIMS study
HM Calls for Transparent CDSCO to Ensure Quality
USFDA approval granted for the drug used for Colon Cleansing
USFDA issues positive EIR to Lupin Limited at Gujarat
Drug Rules to include excipient details in drug labels
USFDA approval granted for the drug for the treatment of Migraine
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
